Patents by Inventor Linda Liu
Linda Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250084164Abstract: Compositions and methods of use thereof for modulating LAIR-1 are provided. For example, immunomodulatory agents are provided that reduce LAIR-1 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to increase an immune response in a subject in need thereof. Exemplary agents include (i) a soluble LAIR-2 polypeptide or fusion protein, (ii) a soluble LAIR 1 polypeptide or fusion protein, (iii) a function blocking anti-LAIR-1 antibody, (iv) an antibody that depletes LAIR-1 positive cells, and (v) combinations thereof. Immunomodulatory agents are also provided that increase LAIR-1 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to reduce an immune response in a subject in need thereof. Exemplary agents include: (i) a function activating anti-LAIR-1 antibody, (ii) a function blocking anti-LAIR-2 antibody, and (iii) a combination thereof.Type: ApplicationFiled: July 15, 2024Publication date: March 13, 2025Inventors: Dallas Benjamin Flies, Linda Liu, Solomon Langermann
-
Publication number: 20250084064Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.Type: ApplicationFiled: November 26, 2024Publication date: March 13, 2025Applicant: Merck Sharp & Dohme LLCInventors: Ashok Arasappan, Ian M. Bell, Michael J. Breslin, Christopher James Bungard, Christopher S. Burgey, Harry R. Chobanian, Jason M. Cox, Anthony T. Ginnetti, Deodial Guy Guiadeen, Kristen L.G. Jones, Mark E. Layton, Hong Liu, Jian Liu, James J. Perkins, Shawn J. Stachel, Linda M. Suen-Lai, Zhe Wu
-
Patent number: 12223524Abstract: Systems, methods, and computer-readable media are disclosed for determining virtual product placement opportunities in a media content and determining product candidates for virtual insertion into the media content. The product placement system may determine shot segments from the media content and for each shot segment may determine candidate product placement locations. The product placement system may determine contextual information from the shot segments and from the contextual information determine candidate products suitable for the product placement locations. The product placement system may determine total screen time for each product placement opportunity as well as quality of each opportunity. For each product and product placement opportunity, the product placement system may determine an expected revenue and a projected insertion cost.Type: GrantFiled: June 23, 2022Date of Patent: February 11, 2025Assignee: Amazon Technologies, Inc.Inventors: Mauricio Alejandro Flores Rios, Han-Kai Hsu, Yujia Chen, Linda Liu, Yash Chaturvedi
-
Patent number: 12084495Abstract: Compositions and methods of use thereof for modulating LAIR-1 are provided. For example, immunomodulatory agents are provided that reduce LAIR-1 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to increase an immune response in a subject in need thereof. Exemplary agents include (i) a soluble LAIR-2 polypeptide or fusion protein, (ii) a soluble LAIR-1 polypeptide or fusion protein, (iii) a function blocking anti-LAIR-1 antibody, (iv) an antibody that depletes LAIR-1 positive cells, and (y) combinations thereof. Immunomodulatory agents are also provided that increase LAIR-1 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to reduce an immune response in a subject in need thereof. Exemplary agents include: (i) a function activating anti-LAIR-1 antibody, (ii) a function blocking anti-LAIR-2 antibody, and (iii) a combination thereof.Type: GrantFiled: August 3, 2017Date of Patent: September 10, 2024Assignee: NEXTCURE, INC.Inventors: Dallas Benjamin Flies, Linda Liu, Solomon Langermann
-
Publication number: 20230357384Abstract: Compositions and methods of use thereof for modulating FLRT3 mediated signaling are provided. For example, immunomodulatory agents are provided that reduce FLRT3 expression, ligand binding, crosslinking, FLRT3 mediated signaling, or a combination thereof. In another embodiment, immunomodulatory agents are provided that enhance or promote FLRT3 expression, ligand binding, crosslinking, FLRT3 mediated signaling, or a combination thereof. Such agents can be used to modulate an immune response in a subject in need thereof.Type: ApplicationFiled: June 21, 2021Publication date: November 9, 2023Applicant: NEXTCURE, INC.Inventors: Dallas Benjamin FLIES, Kushal PRAJAPATI, Adem Can KOKSAL, Linda LIU, Solomon LANGERMANN
-
Patent number: 11789018Abstract: Methods for rapidly concentrating a food sample for efficient detection of bacteria are disclosed. A microfiltration approach followed by centrifugation was used to concentrate the cells with an enzyme (e.g., a protease) added at the beginning of the process to facilitate more efficient micro-filtering. The enzyme was found to have no significant effect on cell viability.Type: GrantFiled: July 22, 2016Date of Patent: October 17, 2023Assignee: Purdue Research FoundationInventors: Michael Ralph Ladisch, Eduardo de Aquino Ximenes, Seockmo Ku, Kirk Solon Foster, Thomas Richard Kreke, Xingya (Linda) Liu, James Thomas Jones, Amanda Deering, Jaycey Hardenstein, Alisha Tungare
-
Patent number: 11390675Abstract: Siglec-15 binding molecules are provides. The molecules are typically an antibody or antigen binding fragment thereof that immunospecifically binds to Siglec-15. Siglec-15 ligand-binding molecules are also provided. The molecules are typically Siglec-15 polypeptide or fusion protein. Methods of using the molecules to reduce Siglec-15 mediated immunosuppression in a subject in need thereof are also provided.Type: GrantFiled: September 21, 2017Date of Patent: July 19, 2022Assignee: NEXTCURE, INC.Inventors: Linda Liu, Benjamin Dallas Flies, Solomon Langermann
-
Publication number: 20210363240Abstract: Compositions and methods of use thereof for modulating LAIR-1 are provided. For example, immunomodulatory agents are provided that reduce LAIR-1 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to increase an immune response in a subject in need thereof. Exemplary agents include (i) a soluble LAIR-2 polypeptide or fusion protein, (ii) a soluble LAIR-1 polypeptide or fusion protein, (iii) a function blocking anti-LAIR-1 antibody, (iv) an antibody that depletes LAIR-1 positive cells, and (y) combinations thereof. Immunomodulatory agents are also provided that increase LAIR-1 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to reduce an immune response in a subject in need thereof. Exemplary agents include: (i) a function activating anti-LAIR-1 antibody, (ii) a function blocking anti-LAIR-2 antibody, and (iii) a combination thereof.Type: ApplicationFiled: August 3, 2017Publication date: November 25, 2021Inventors: Dallas Benjamin Flies, Linda Liu, Solomon Langermann
-
Publication number: 20210032346Abstract: Compositions and methods of use thereof for modulating B7-H4 are provided. For example, immunomodulatory agents are provided that reduce B7-H4 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to increase an immune response in a subject in need thereof. Immunomodulatory agents are also provided that increase B7-H4 expression, ligand binding, crosslinking, negative signaling, or a combination thereof. Such agents can be used to reduce an immune response in a subject in need thereof.Type: ApplicationFiled: January 23, 2019Publication date: February 4, 2021Inventors: Solomon Langermann, Dallas Benjamin Flies, Linda LIU
-
Publication number: 20210002373Abstract: Compositions that bind to killer cell lectin-like receptor G1 (KLRG1) or its ligands are provided. The compositions can agonize or antagonize signal transduction through KLRG1. For example, some compositions either inhibit or block signal transduction through KLRG1 while other compositions induce or enhance signal transduction through KLRG1. In some embodiments, the compositions are anti-KLRG1 antibodies, KLRG1 fusion proteins, or KLRG1 ligand fusion proteins. One embodiment provides antibodies and antigen binding fragments thereof that immuno specifically bind KLRG1 and block, inhibit or reduce signal transduction through KLRG1. In another embodiment, the antibodies specifically bind to human KLRG1 under physiological conditions.Type: ApplicationFiled: March 1, 2019Publication date: January 7, 2021Inventors: Linda LIU, Dallas Benjamin Flies
-
Patent number: 10615877Abstract: An electro-absorption bias circuit may include a temperature sensor. The electro-absorption bias circuit may include a controller to provide a temperature-dependent control signal based on data received from the temperature sensor. The electro-absorption bias circuit may include a power supply to provide an output voltage based on the temperature-dependent control signal from the controller. The electro-absorption bias circuit may include an electro-absorption driving circuit to output a bias voltage applied to the output voltage provided by the power supply.Type: GrantFiled: May 23, 2018Date of Patent: April 7, 2020Assignee: Lumentum Operations LLCInventors: Ricardo Saad, Linda Liu, Yu-Ting Hsueh, Goutham Kumar
-
Publication number: 20190202912Abstract: Siglec-15 binding molecules are provides. The molecules are typically an antibody or antigen binding fragment thereof that immunospecifically binds to Siglec-15. Siglec-15 ligand-binding molecules are also provided. The molecules are typically Siglec-15 polypeptide or fusion protein. Methods of using the molecules to reduce Siglec-15 mediated immunosuppression in a subject in need thereof are also provided.Type: ApplicationFiled: September 21, 2017Publication date: July 4, 2019Inventors: Linda Liu, Benjamin Dallas Flies, Solomon Langermann
-
Patent number: 10316092Abstract: The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H5 ligand of the B7-H5:CD28H pathway, and to the uses of such molecules in the treatment and diagnosis of autoimmune disease, transplant rejection and other inflammatory diseases.Type: GrantFiled: May 27, 2014Date of Patent: June 11, 2019Assignees: THE JOHN HOPKINS UNIVERSITY, MEDIMMUNE, LLCInventors: Sheng Yao, Lieping Chen, Linda Liu, Solomon Langermann
-
Publication number: 20190068288Abstract: An electro-absorption bias circuit may include a temperature sensor. The electro-absorption bias circuit may include a controller to provide a temperature-dependent control signal based on data received from the temperature sensor. The electro-absorption bias circuit may include a power supply to provide an output voltage based on the temperature-dependent control signal from the controller. The electro-absorption bias circuit may include an electro-absorption driving circuit to output a bias voltage applied to the output voltage provided by the power supply.Type: ApplicationFiled: May 23, 2018Publication date: February 28, 2019Inventors: Ricardo SAAD, Linda LIU, Yu-Ting HSUEH, Goutham KUMAR
-
Publication number: 20180180611Abstract: Methods for rapidly concentrating a food sample for efficient detection of bacteria are disclosed. A microfiltration approach followed by centrifugation was used to concentrate the cells with an enzyme (e.g., a protease) added at the beginning of the process to facilitate more efficient micro-filtering. The enzyme was found to have no significant effect on cell viability.Type: ApplicationFiled: July 22, 2016Publication date: June 28, 2018Inventors: Michael Ralph Ladisch, Eduardo de Aquino Ximines, Seockmo Ku, Kirk Solon Foster, Thomas Richard Kreke, Xingya (Linda) Liu, James Thomas Jones, Amanda Deering, Jaycey Hardenstein, Alisha Tungare
-
Patent number: 9957312Abstract: Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1?, TNF-?, TGF-beta, IFN-?, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.Type: GrantFiled: April 6, 2015Date of Patent: May 1, 2018Assignee: MedImmune, LLCInventors: Solomon Langermann, Linda Liu, Joseph R. Podojil, Stephen D. Miller, Shannon Marshall
-
Publication number: 20180079813Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.Type: ApplicationFiled: September 19, 2017Publication date: March 22, 2018Applicants: MEDIMMUNE, LLC, THE JOHNS HOPKINS UNIVERSITYInventors: SOLOMON LANGERMANN, LINDA LIU, SHENG YAO, LIEPING CHEN
-
Publication number: 20180066056Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.Type: ApplicationFiled: September 19, 2017Publication date: March 8, 2018Applicants: MEDIMMUNE, LLC, THE JOHNS HOPKINS UNIVERSITYInventors: SOLOMON LANGERMANN, LINDA LIU, SHENG YAO, LIEPING CHEN
-
Patent number: 9790277Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, H7CR, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.Type: GrantFiled: December 23, 2013Date of Patent: October 17, 2017Assignees: The Johns Hopkins University, MedImmune, LLCInventors: Solomon Langermann, Linda Liu, Sheng Yao, Lieping Chen
-
Patent number: 9676854Abstract: The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases. The invention particularly concerns the use of such molecules to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM—mediated immune suppression.Type: GrantFiled: August 15, 2012Date of Patent: June 13, 2017Assignee: MedImmune, LLCInventors: Linda Liu, Shannon Marshall, Solomon Langermann